Efficacy and Safety of Phosphatidylinositol 3-kinase Inhibitors for Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials
CONCLUSION: PI3K inhibitors had better efficacy than the present standard of concern for patients with breast cancer, especially among patients with PIK3CA mutations. Hence, clinicians and oncologists can provide this drug for the target population with extra caution for diabetes patients.PMID:38275057 | DOI:10.2174/0115680096266181231207110048 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - January 26, 2024 Category: Cancer & Oncology Authors: Yi Wang Xianling Du Hongqiang Xin Ruimin Xu Source Type: research
Prognostic Significance and Functional Mechanism of UTS2 in Glioblastoma Multiforme
CONCLUSION: Our study identified that UTS2 could predict the prognosis of GBM patients and provided evidence regarding its oncogenic effects both in vitro and in vivo.PMID:38265405 | DOI:10.2174/0115680096275291231226081320 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - January 24, 2024 Category: Cancer & Oncology Authors: Yanfei Wang Langping Shen Mingzhong Sun Source Type: research
Immunologic Crosstalk of Endoplasmic Reticulum Stress Signaling in Bladder Cancer
This article provides an overview of the recent developments in understanding how ER stress influences tumor immunity and its implications for BC. Targeting this pathway may soon emerge as a compelling therapeutic strategy for BC.PMID:38265406 | DOI:10.2174/0115680096272663231121100515 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - January 24, 2024 Category: Cancer & Oncology Authors: Shun Wan Kun-Peng Li Chen-Yang Wang Jian-Wei Yang Si-Yu Chen Hua-Bin Wang Xiao-Ran Li Li Yang Source Type: research
Tectorigenin Inhibits Glycolysis-induced Cell Growth and Proliferation by Modulating LncRNA CCAT2/miR-145 Pathway in Colorectal Cancer
CONCLUSION: Tec can inhibit the proliferation and glycolysis of CRC cells through the lncRNA CCAT2/miR-145 axis. Altogether, the potential targets discovered in this research are of great significance for CRC treatment and new drug development.PMID:38243936 | DOI:10.2174/0115680096274757231219072003 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - January 20, 2024 Category: Cancer & Oncology Authors: Ying Xing Bofan Lin Baoxinzi Liu Jie Shao Zhichao Jin Source Type: research
The Tumor Immune Microenvironment plays a Key Role in Driving the Progression of CholangioCarcinoma
Curr Cancer Drug Targets. 2024 Jan 11. doi: 10.2174/0115680096267791231115101107. Online ahead of print.ABSTRACTCholangiocarcinoma (CCA) is an epithelial cancer distinguished by bile duct cell differentiation and is also a fibroproliferative tumor. It is characterized by a dense mesenchyme and a complex tumor immune microenvironment (TME). The TME comprises both cellular and non-cellular components. The celluar component includes CCA cells, immune cells and mesenchymal cells represented by the cancer-associated fibroblasts (CAFs), while the non-cellular component is represented by mesenchymal elements such as the extracell...
Source: Current Cancer Drug Targets - January 12, 2024 Category: Cancer & Oncology Authors: Ye Zhang Hai-Jiao Yan Jun Wu Source Type: research
Investigating the Influence of Gut Microbiota-related Metabolites in Gastrointestinal Cancer
Curr Cancer Drug Targets. 2024 Jan 11. doi: 10.2174/0115680096274860231111210214. Online ahead of print.ABSTRACTGastrointestinal (GI) cancer is a major health concern due to its prevalence, impact on well-being, high mortality rate, economic burden, and potential for prevention and early detection. GI cancer research has made remarkable strides in understanding biology, risk factors, and treatment options. An emerging area of research is the gut microbiome's role in GI cancer development and treatment response. The gut microbiome, vital for digestion, metabolism, and immune function, is increasingly linked to GI cancers. D...
Source: Current Cancer Drug Targets - January 12, 2024 Category: Cancer & Oncology Authors: Zeynab Marzhoseyni Zahra Shaghaghi Maryam Alvandi Maria Shirvani Source Type: research
Deubiquitylase USP31 Induces Autophagy and Promotes the Progression in Lung Squamous Cell Carcinoma Cells by Stabilizing E2F1 Expression
CONCLUSION: In summary, this investigation proved that USP31 promoted LUSC cell growth and autophagy, at least in part by stabilizing E2F1 expression, which provided a potential therapeutic gene for the treatment of LUSC.PMID:38204265 | DOI:10.2174/0115680096264557231124102054 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - January 11, 2024 Category: Cancer & Oncology Authors: Wenjun Liang Mingxia Yang Xiaohua Wang Yan Qian Ruichen Gao Yujia Shi Xuejun Shi Lei Shi Ting Xu Qian Zhang Source Type: research
Establishment and Validation of a Blood Test-based Nomogram to Diagnose Patients with AFP-negative HCC
CONCLUSION: This proposed nomogram was an accurate and useful method to distinguish patients with AFP-negative HCC from liver cirrhosis.PMID:38178672 | DOI:10.2174/0115680096264770231113103930 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - January 5, 2024 Category: Cancer & Oncology Authors: Yujing Wu Shuang Liu Zhijuan Fan Yaqiong Tian Lei Zhang Shuye Liu Source Type: research
Naringenin-induced Oral Cancer Cell Apoptosis Via ROS-mediated Bid and Bcl-xl Signaling Pathway
CONCLUSION: The findings suggested that naringenin may represent a promising candidate for the treatment of oral cancer by inducing apoptotic cell death via modulation of the Bid and Bcl-xl signaling pathways.PMID:38178673 | DOI:10.2174/0115680096267430231023091521 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - January 5, 2024 Category: Cancer & Oncology Authors: YuYe Du Jia Lai Jingyao Su Jiali Li Chuqing Li Bing Zhu Yinghua Li Source Type: research
CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells
CONCLUSIONS: These data suggest that further preclinical and clinical development of CT109-SN-38 is warranted.PMID:38178674 | DOI:10.2174/0115680096260614231115192343 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - January 5, 2024 Category: Cancer & Oncology Authors: Kelly C Arias Cardenas Clinton W Enos Mark R Spear Dana E Austin Raghad Almofeez Stephanie Kortchak Lauren Pincus Hua-Bei Guo Samuel Dolezal J Michael Pierce Emma Furth Cyrille Gineste Yongjun Kwon Cohava Gelber Source Type: research
Establishment and Validation of a Blood Test-based Nomogram to Diagnose Patients with AFP-negative HCC
CONCLUSION: This proposed nomogram was an accurate and useful method to distinguish patients with AFP-negative HCC from liver cirrhosis.PMID:38178672 | DOI:10.2174/0115680096264770231113103930 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - January 5, 2024 Category: Cancer & Oncology Authors: Yujing Wu Shuang Liu Zhijuan Fan Yaqiong Tian Lei Zhang Shuye Liu Source Type: research
Naringenin-induced Oral Cancer Cell Apoptosis Via ROS-mediated Bid and Bcl-xl Signaling Pathway
CONCLUSION: The findings suggested that naringenin may represent a promising candidate for the treatment of oral cancer by inducing apoptotic cell death via modulation of the Bid and Bcl-xl signaling pathways.PMID:38178673 | DOI:10.2174/0115680096267430231023091521 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - January 5, 2024 Category: Cancer & Oncology Authors: YuYe Du Jia Lai Jingyao Su Jiali Li Chuqing Li Bing Zhu Yinghua Li Source Type: research
CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells
CONCLUSIONS: These data suggest that further preclinical and clinical development of CT109-SN-38 is warranted.PMID:38178674 | DOI:10.2174/0115680096260614231115192343 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - January 5, 2024 Category: Cancer & Oncology Authors: Kelly C Arias Cardenas Clinton W Enos Mark R Spear Dana E Austin Raghad Almofeez Stephanie Kortchak Lauren Pincus Hua-Bei Guo Samuel Dolezal J Michael Pierce Emma Furth Cyrille Gineste Yongjun Kwon Cohava Gelber Source Type: research
Establishment and Validation of a Blood Test-based Nomogram to Diagnose Patients with AFP-negative HCC
CONCLUSION: This proposed nomogram was an accurate and useful method to distinguish patients with AFP-negative HCC from liver cirrhosis.PMID:38178672 | DOI:10.2174/0115680096264770231113103930 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - January 5, 2024 Category: Cancer & Oncology Authors: Yujing Wu Shuang Liu Zhijuan Fan Yaqiong Tian Lei Zhang Shuye Liu Source Type: research
Naringenin-induced Oral Cancer Cell Apoptosis Via ROS-mediated Bid and Bcl-xl Signaling Pathway
CONCLUSION: The findings suggested that naringenin may represent a promising candidate for the treatment of oral cancer by inducing apoptotic cell death via modulation of the Bid and Bcl-xl signaling pathways.PMID:38178673 | DOI:10.2174/0115680096267430231023091521 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - January 5, 2024 Category: Cancer & Oncology Authors: YuYe Du Jia Lai Jingyao Su Jiali Li Chuqing Li Bing Zhu Yinghua Li Source Type: research
